常见EGFR突变高级非小细胞肺癌的当前和新兴治疗景观
David John McMahon1, Alexius John1, Sanjay Popat2
1Royal Marsden Hospital, 203 Fulham Road, Chelsea, London, SW36JJ, UK.
Targeted oncology
|January 29, 2026
概括
奥西默提尼布是EGFR突变非小细胞肺癌的标准药物. 新的策略和抵抗机制使治疗序列复杂化,需要对基因组的理解才能获得最佳的患者结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
背景情况:
- 作为第三代EGFR TKI的奥西默蒂尼布是EGFR突变NSCLC的标准.
- 组合疗法 (化疗,EGFR/MET联合抑制) 是新兴的标准.
- 了解疾病生物学和患者特异性因素对于治疗选择至关重要.
研究的目的:
- 为 EGFR 突变性 NSCLC 提供当前和未来的药物治疗策略的概述.
- 探索在第一线和后一线设置中指导治疗选择的细微差别.
- 为了应对最佳治疗选择和测序的挑战.
主要方法:
- 对临床试验数据的审查 (例如,FLAURA).
- 获得性抵抗机制的分析.
- 探索新的治疗方法 (例如,ADC,VEGF抑制剂,免疫疗法).
主要成果:
- 一线策略已经发展,使二线决策变得更加复杂.
- 使用第四代TKI向目标耐药性 (例如C797X) 的成功有限.
- 为了改善二线结果,正在开发多种更广泛的方法.
结论:
- 在EGFR突变NSCLC中选择和测序最佳疗法是一个重大挑战.
- 基因组分析和在进展时的重新评估对于指导下一线治疗至关重要.
- 未来的战略需要仔细考虑生物和监管的复杂性.
更多相关视频
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
9.3K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.6K
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
14.9K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Mutations
94.5K
Overview
94.5K
Mutations
44.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Common Ion Effect
46.6K
Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Châtelier’s principle. Consider the dissolution of silver iodide:
46.6K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
